n a significant shift, total spending on medicines in the US rose by 5.8 percent, to $450 billion, in 2016, which was less than half the rate seen in the last two years. In 2015, for instance, drug spending climbed 8.9 percent and it had rocketed up by 12 percent the year before.

However, when subtracting rebates and discounts that drug makers pay insurers, net spending was $323 billion, a 4.8 increase over 2015, according to a new report from the Quintiles/IMS Institute. The increase in total spending last year, which amounted to $27.3 billion on an invoice price basis and $14.8 billion on a net basis, was largely driven by new brands and patent-protected brands.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy